LMY-932

LMY-932 is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy being developed by Luminary Therapeutics. It utilizes gamma delta (γδ) T cells as the cellular vehicle, which are known for their innate-like recognition properties and potential for allogeneic (off-the-shelf) application. The program is currently being investigated for the treatment of autoimmune conditions, specifically rheumatoid arthritis, as well as B-cell malignancies such as chronic lymphatic leukemia (CLL). While the specific antigen target for LMY-932 has not been publicly disclosed in current pipeline documentation, the therapy aims to leverage the unique biology of γδ T cells to address limitations of conventional αβ CAR-T therapies, potentially offering improved safety and efficacy in both solid and hematologic environments.